Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

NCT07571746 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07571746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07571746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
March 28, 2026
Completion date
October 15, 2029
Enrollment
43 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy